Yes, obtain a low-dose whole-body CT skeletal survey in this patient with IgG paraprotein and immune paresis.
A patient presenting with an IgG paraprotein and immune paresis requires skeletal imaging to exclude multiple myeloma, and low-dose whole-body CT is now the preferred modality over conventional skeletal radiography. 1, 2
Rationale for Imaging
The presence of immune paresis (suppression of uninvolved immunoglobulins) alongside a paraprotein significantly elevates concern for multiple myeloma rather than benign MGUS. This combination warrants complete diagnostic workup including:
- Bone marrow examination
- Skeletal imaging to detect osteolytic lesions (myeloma-defining events)
- Laboratory assessment including serum free light chains, β2-microglobulin, and LDH
Why CT Over Conventional Radiography
Low-dose whole-body CT has replaced conventional skeletal surveys as the first-line imaging modality for several compelling reasons 2:
- Superior sensitivity: CT detects significantly more lytic lesions than plain radiographs, particularly in the spine and ribs
- Patient comfort: Single acquisition versus multiple radiographic views
- Faster acquisition: Completed in minutes rather than the prolonged positioning required for skeletal survey
- Lower radiation: Modern protocols achieve effective doses of 1.5-2.6 mSv 3, comparable to or less than conventional skeletal surveys 4
- Better assessment of fracture risk: Superior visualization of cortical bone destruction and soft tissue involvement
The 2014 IMWG criteria specifically incorporated whole-body CT as an acceptable alternative to skeletal survey 2. More recent evidence from 2018 IMWG Bone Working Group recommendations provides standardized protocols for CT acquisition and interpretation 2.
Clinical Context Matters
While the 2014 European Myeloma Network guidelines suggest that imaging may not be routinely required for IgG M-protein ≤15 g/L without bone pain 1, the presence of immune paresis changes this calculus entirely. Immune paresis indicates more advanced disease biology and substantially increases the probability of finding:
- ≥10% clonal plasma cells on bone marrow biopsy
- Osteolytic lesions on imaging
- Other myeloma-defining events
The Italian study cited in the guidelines showed very low probability (1.7-2%) of bone lesions in asymptomatic patients with low IgG levels 1, but those data apply to patients without immune paresis.
What to Look For on CT
The radiologist should specifically assess for 2:
- Osteolytic lesions: Any size, but particularly ≥5 mm
- Cortical destruction: Indicates high fracture risk
- Soft tissue components: Paraskeletal or extramedullary disease
- Pathologic fractures: Especially in weight-bearing bones
- Diffuse osteopenia: May indicate diffuse marrow involvement
Additional Imaging Considerations
If the whole-body CT is negative for osteolytic lesions but clinical suspicion remains high (particularly if bone marrow shows ≥10% plasma cells), consider adding whole-body MRI 5, 1. MRI can detect:
- Focal marrow lesions (>1 focal lesion ≥5 mm is a myeloma-defining event)
- Diffuse marrow infiltration
- Bone marrow involvement before cortical bone destruction occurs
However, start with CT as the initial imaging modality given its widespread availability, standardized protocols, and ability to detect the most clinically relevant finding: osteolytic bone destruction requiring treatment.
Common Pitfalls to Avoid
- Don't delay imaging waiting for symptoms: Bone pain is a late finding; asymptomatic lytic lesions are common
- Don't use standard-dose CT protocols: Low-dose protocols (effective dose ~1.5-2.6 mSv) are adequate and validated 3
- Don't rely on bone scan: Nuclear medicine bone scans are insensitive for myeloma (lytic lesions don't show increased uptake)
- Don't skip imaging based solely on M-protein level: Immune paresis indicates higher-risk disease regardless of paraprotein quantity
The combination of IgG paraprotein with immune paresis mandates complete staging evaluation, and low-dose whole-body CT represents the current standard of care for skeletal assessment in this clinical scenario.